Since Jan 2010,
Selleck products have
been cited in 431
studies from top
scientific journals.

14 Nobel Prize winners have published 45 articles with Selleck products.

David Julius

Won the Nobel Prize in Physiology or Medicine in 2021


Michael Houghton

Won the Nobel Prize in Physiology or Medicine in 2020


Peter J. Ratcliffe

Won the Nobel Prize in Physiology or Medicine in 2019


Gregg L. Semenza

Won the Nobel Prize in Physiology or Medicine in 2019


James P. Allison

Won the Nobel Prize in Physiology or Medicine in 2018


Michael Rosbash

Won the Nobel Prize in Physiology or Medicine in 2017


Eric Richard Kandel

Won the Nobel Prize in Physiology or Medicine in 2000


Brian K. Kobilka

Won the Nobel Prize in Chemistry in 2012


Robert Lefkowitz

Won the Nobel Prize in Chemistry in 2012


Aaron Ciechanover

Won the Nobel Prize in Chemistry in 2004


Compound Libraries

FDA-approved Drug Library


A unique collection of 3038 approved drugs for high throughput screening (HTS) and high content screening (HCS).

FDA-approved & Passed Phase I Drug Library


A unique collection of 3337 drugs that are marketed around the world or have passed clinical phase 1 and can be used for high throughput screening (HTS) and high content screening (HCS).

Preclinical/Clinical Compound Library


A unique collection of 3103 preclinical and clinical compounds for high throughput screening (HTS) and high content screening (HCS).

Bioactive Compound Library-I


A unique collection of 8273 bioactive compounds for high throughput screening (HTS) and high content screening (HCS).

Bioactive Compound Library-Ⅱ


A unique collection of 5309 bioactive compounds for high throughput screening (HTS) and high content screening (HCS).

Kinase Inhibitor Library


A unique collection of 1796 kinase inhibitors for high throughput screening (HTS) and high content screening (HCS).

Express-Pick Library


A unique collection of 3010 chemical compounds featured different core structures and structural diversities respectively for high throughput screening (HTS) and high content screening (HCS).

Natural Product Library


A unique collection of 2661 natural products for high throughput screening (HTS) and high content screening (HCS).

Human Endogenous Metabolite Compound Library


1021 small collections of human endogenous metabolites, involving multiple metabolic pathways, which can be used for high-throughput screening, opening up new ways for humans to treat various diseases such as tumors.

Alkaloid Compound Library


A unique collection of 413 alkaloid compounds used for high throughput screening(HTS) and high content screening(HCS).

New Products

G150


G150 is a potent and highly selective human cyclic GMP-AMP synthase (h-cGAS) inhibitor with IC50 of 10.2 nM.

TH5487


TH5487 is a selective active-site inhibitor of 8-oxoguanine DNA glycosylase 1 (OGG1) with IC50 of 342 nM.

KGA-2727


KGA-2727 is a potent, selective, high-affinity inhibitor of sodium glucose cotransporter 1 (SGLT1) with Ki of 97.4 nM and 43.5 nM for human SGLT1 and rat SGLT1, respectively. The selectivity ratios (Ki for SGLT2/Ki for SGLT1) of KGA-2727 are 140 (human) and 390 (rat). KGA-2727 exhibits antidiabetic efficacy in rodent models.

Mizagliflozin


Mizagliflozin is a novel, potent, selective sodium glucose co-transporter 1 (SGLT1) inhibitor with Ki of 27 nM for human SGLT1. The selectivity ratio (Ki value for human SGLT2/Ki value for human SGLT1) of mizagliflozin is 303. Mizagliflozin shows the potential use for the amelioration of chronic constipation.

Guadecitabine (SGI-110)


Guadecitabine (SGI-110) is a next-generation hypomethylating agent whose active metabolite decitabine has a longer in-vivo exposure time than intravenous decitabine.

CM272


CM-272 is a novel first-in-class dual reversible inhibitor of G9a (GLP) and DNMTs with IC50 of 8 nM, 382 nM, 85 nM, 1200 nM, 2 nM for G9a, DNMT1, DNMT3A, DNMT3B, GLP, respectively. CM-272 prolongs survival in in vivo models of haematological malignancies by at least in part inducing immunogenic cell death.

Visomitin (SKQ1)


INT-777 (S-EMCA) is a novel potent and selective TGR5 agonist with EC50 values of 0.18 μM, 3.9 μM and 1.45 μM for WT TGR5, TGR5(N76A) and TGR5(Y89F) respectively.

BAY1125976


BAY 1125976 is a selective allosteric AKT1/2 inhibitor,exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models. BAY1125976 inhibits the activity of AKT1 (IC50 = 5.2 nM at 10 µM ATP and 44 nM at 2 mM ATP) and AKT2 (IC50 = 18 nM at 10 µM ATP and 36 nM at 2 mM ATP) very potently.Whereas BAY1125976 is almost inactive on AKT3 (IC50 = 427 nM at 10 µM ATP).

Tags: kinase inhibitors, tyrosine kinase inhibitors, enzyme inhibitors, protein inhibitors, proteins kinase inhibitors, small molecules, phosphatase inhibitors